8th Feb 2008 07:00
Skyepharma PLC08 February 2008 SkyePharma Announces Collaboration with Dr Reddy's Laboratories for New Product Utilizing Two of SkyePharma's Proprietary Drug Delivery Systems. LONDON, UK, 8 February, 2008 - SkyePharma PLC (LSE: SKP) today announces that ithas entered into an agreement with Dr Reddy's Laboratories (NYSE: RDY) toundertake a feasibility study. The costs of this study, of a product utilizingtwo of SkyePharma's proprietary drug delivery systems, will be paid for by DrReddy's. SkyePharma will also receive a small upfront payment. If thefeasibility study is successful, full development activities will begin laterthis year. SkyePharma's Chief Executive Officer, Frank Condella, said: "We are very pleasedto enter into this collaboration with Dr Reddy's on a new product developmentopportunity and hope to extend the collaboration to other products." For further information please contact: SkyePharma PLC Frank Condella +44 20 7491 1777During office hours Ken Cunningham Peter Grant Financial Dynamics (UK Enquiries) David Yates +44 20 7831 3113Outside office hours Deborah Scott Trout Group (US Enquiries) Christine Labaree +1 617 583 1308 Seth Lewis About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops newformulations of known molecules to provide a clinical advantage and life-cycleextension. The Company has twelve approved products in the areas of oral,inhalation and topical delivery. The Group's products are marketed throughoutthe world by leading pharmaceutical companies. For more information, visitwww.skyepharma.com About Dr Reddy's Laboratories Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging globalpharmaceutical company with proven research capabilities. The Company isvertically integrated with a presence across the pharmaceutical value chain. Itproduces finished dosage forms, active pharmaceutical ingredients andbiotechnology products and markets them globally, with focus on India, US,Europe and Russia. The company conducts research in the areas of cancer,diabetes, cardiovascular, inflammation and bacterial infection.(www.drreddys.com) This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
SKP.L